

Commissioner of Patents
USSN 10/661,415

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (currently amended): A method for the prophylaxis or treatment of a RSV or parainfluenza virus infection in a subject, comprising

administering to a subject in need of such treatment a therapeutically effective amount of a pharmacological acceptable oligonucleotide of at least 20 nucleotides in length, wherein said oligonucleotide comprises at least one phosphorothioated linkage, does not comprise an immune system interacting CpG proton, is not complementary to any portion of the genomic sequence of RSV or parainfluenza virus, and is not complementary to any RSV or parainfluenza virus mRNA sequence and wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.

Claim 2 (currently amended): ~~The method of claim 1, wherein said subject is a human~~ A method for the prophylaxis or treatment of a RSV or parainfluenza virus infection in a subject, comprising

administering to a subject in need of such treatment a therapeutically effective amount of a pharmacological acceptable oligonucleotide of at least 20 nucleotides in length, wherein said oligonucleotide comprises only sequences selected from the group consisting of AA, CC, GG, TT, AC, CA, AG, GA, AT, TA, CT, TC, GT and TG, is not complementary to any portion of the genomic sequence of RSV or parainfluenza virus, and is not complementary to any RSV or parainfluenza virus mRNA sequence and wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.

Claims 3-13 (Cancelled).

Claim 14 (currently amended): ~~The method of claim 1, wherein said oligonucleotide randomer oligonucleotide~~ A method for the prophylaxis or treatment of a RSV or parainfluenza virus infection in a subject, comprising

administering to a subject in need of such treatment a therapeutically effective amount of a pharmacological acceptable oligonucleotide of at least 20 nucleotides in length, wherein said oligonucleotide comprises at least one phosphorothioated

Commissioner of Patents
USSN 10/661,415

linkage, comprises only nucleotides selected from the group consisting of C, A and T, is not complementary to any portion of the genomic sequence of RSV or parainfluenza virus, and is not complementary to any RSV or parainfluenza virus mRNA sequence and wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.

Claim 15-42 (Cancelled).